Highlights Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Market Closed - Nasdaq Other stock markets 21:30:01 17/05/2024 BST			5-day change	1st Jan Change
2.29 ^USD	+1.33%		+7.76%	-81.59%

05-14	Transcript : Vivos Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
05-14	Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q1 Revenue $3.4M	05-14	MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	04-01	MT
Top Premarket Decliners	04-01	MT
Vivos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q4 Revenue $3.2M	03-28	MT
Vivos Therapeutics, Inc. Receives FDA Clearance to Vivos Care Oral Appliances to Treat Severe OSA in Adults	02-06	CI
Vivos Therapeutics, Inc. Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company's Proprietary Oral Medical Devices to Treat Severe OSA	01-08	CI
Vivos Therapeutics Receives FDA 510(k) Clearance for Oral Device Treatment for Sleep Apnea; Shares Soar	11-29	MT
Vivos Therapeutics, Inc. Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea	11-29	CI
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q3 Revenue $3.3M, vs. Street Est of $4.14M	11-14	MT
Vivos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/08/23	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q2 Revenue $3.4M, vs. Street Est of $4.1M	16/08/23	MT
Vivos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/06/23	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Reports Q1 Revenue $3.9M, vs. Street Est of $4.01M	08/06/23	MT
Vivos Therapeutics, Inc. Announces Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos’ Po Appliance Treatment	01/05/23	CI
Vivos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Earnings Flash (VVOS) VIVOS THERAPEUTICS Posts Q4 Revenue $4M	30/03/23	MT
Vivos Therapeutics Regains Nasdaq Listing Compliance	20/01/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vivos Therapeutics, Inc.

Equities

VVOS

US92859E2072

Highlights

Filters